erlotinib has been researched along with N-(3-ethynylphenyl)-6,7-dimethoxy-4-quinazolinamine in 5 studies
| Studies (erlotinib) | Trials (erlotinib) | Recent Studies (post-2010) (erlotinib) | Studies (N-(3-ethynylphenyl)-6,7-dimethoxy-4-quinazolinamine) | Trials (N-(3-ethynylphenyl)-6,7-dimethoxy-4-quinazolinamine) | Recent Studies (post-2010) (N-(3-ethynylphenyl)-6,7-dimethoxy-4-quinazolinamine) |
|---|---|---|---|---|---|
| 221 | 0 | 180 | 11 | 0 | 7 |
| Protein | Taxonomy | erlotinib (IC50) | N-(3-ethynylphenyl)-6,7-dimethoxy-4-quinazolinamine (IC50) |
|---|---|---|---|
| Cyclin-G-associated kinase | Homo sapiens (human) | 0.072 | |
| Epidermal growth factor receptor | Homo sapiens (human) | 0.038 | |
| Fructose-1,6-bisphosphatase 1 | Sus scrofa (pig) | 1.6 | |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 0.0705 | |
| Fructose-1,6-bisphosphatase 1 | Homo sapiens (human) | 0.9 | |
| Receptor tyrosine-protein kinase erbB-3 | Homo sapiens (human) | 0.0705 | |
| Receptor tyrosine-protein kinase erbB-4 | Homo sapiens (human) | 0.0705 | |
| Histamine H3 receptor | Rattus norvegicus (Norway rat) | 0.9 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, SF; Liu, HH; Liu, LT; Wu, YT; Yuan, TT | 1 |
| Heynck, S; Pawar, VG; Rabiller, M; Rauh, D; Rode, HB; Sos, ML; Thomas, RK; van Otterlo, WA | 1 |
| Asquith, CRM; Drewry, DH; East, MP; Havener, TM; Johnson, GL; Laitinen, T; Morris, DC; Naegeli, KM; Wells, CI; Zuercher, WJ | 1 |
| Asquith, CRM; Crona, DJ; Fleck, N; Grundner, C; Torrice, CD; Zuercher, WJ | 1 |
| Asquith, CRM; Einav, S; Huang, PT; Saul, S | 1 |
5 other study(ies) available for erlotinib and N-(3-ethynylphenyl)-6,7-dimethoxy-4-quinazolinamine
| Article | Year |
|---|---|
Synthesis and biological evaluation of substituted 6-alkynyl-4-anilinoquinazoline derivatives as potent EGFR inhibitors.
Topics: Aniline Compounds; Antineoplastic Agents; Computer Simulation; Drug Screening Assays, Antitumor; ErbB Receptors; Inhibitory Concentration 50; Models, Molecular; Molecular Structure; Quinazolines; Structure-Activity Relationship | 2007 |
Synthesis and biological evaluation of 4-anilinoquinolines as potent inhibitors of epidermal growth factor receptor.
Topics: Animals; Cell Line, Tumor; Drug Evaluation, Preclinical; ErbB Receptors; Inhibitory Concentration 50; Models, Molecular; Molecular Conformation; Mutation; Protein Kinase Inhibitors; Quinolines; Structure-Activity Relationship | 2010 |
Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.
Topics: Aminoquinolines; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chordoma; Drug Design; ErbB Receptors; HEK293 Cells; Humans; Intracellular Signaling Peptides and Proteins; Molecular Docking Simulation; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines | 2019 |
Anti-tubercular activity of novel 4-anilinoquinolines and 4-anilinoquinazolines.
Topics: Aniline Compounds; Antitubercular Agents; Dose-Response Relationship, Drug; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Quinazolines; Quinolines; Structure-Activity Relationship | 2019 |
Identification and evaluation of 4-anilinoquin(az)olines as potent inhibitors of both dengue virus (DENV) and Venezuelan equine encephalitis virus (VEEV).
Topics: Aniline Compounds; Antiviral Agents; Dengue Virus; Dose-Response Relationship, Drug; Encephalitis Virus, Venezuelan Equine; Microbial Sensitivity Tests; Molecular Structure; Quinazolines; Structure-Activity Relationship | 2021 |